Maybe, you can try.
But market has also told us, any such expectations in the past few years eventually fell to nothing.
ACR management team is one of the worse (if not the worst) to run a small cap Biotech.
Cash is more than the MC at the moment, but if you think this tells you it is undervalue then you maybe be wrong. Without Axiron income these guys can dry up the $30+ millions cash quicker than you can image.
Add to My Watchlist
What is My Watchlist?
